晚期黑色素瘤一线治疗的疗效与安全性:一项网络荟萃分析
该网络荟萃分析纳入18项随机临床试验的9070例晚期黑色素瘤患者,间接比较一线治疗方案。结果显示瑞拉利单抗/纳武利尤单抗与伊匹木单抗/纳武利尤单抗的无进展生存期和客观缓解率相似,且前者≥3级治疗相关不良事件风险有降低趋势。
要点
- 瑞拉利单抗/纳武利尤单抗与伊匹木单抗/纳武利尤单抗的PFS和ORR无差异。
- PD-(L)1/BRAF/MEK抑制剂三联方案在PFS和ORR上优于伊匹木单抗/纳武利尤单抗。
- 伊匹木单抗/纳武利尤单抗的≥3级治疗相关不良事件风险最高。
核心结论
- 瑞拉利单抗/纳武利尤单抗与伊匹木单抗/纳武利尤单抗相比PFS和ORR相似,且安全性有更优趋势。
研究设计与样本
- 系统综述与网络荟萃分析,纳入18项随机临床试验的9070例晚期黑色素瘤患者。
- 纳入初治晚期黑色素瘤的随机临床试验,至少一个干预组包含BRAF/MEK抑制剂或免疫检查点抑制剂。
主要发现
- 伊匹木单抗/纳武利尤单抗与瑞拉利单抗/纳武利尤单抗的PFS无差异(HR=0.99,95%CI 0.75-1.31),ORR无差异(RR=0.99,95%CI 0.78-1.27)。
- PD-(L)1/BRAF/MEK抑制剂三联方案在PFS(HR=0.56,95%CI 0.37-0.84)和ORR(RR=3.07,95%CI 1.61-5.85)上均优于伊匹木单抗/纳武利尤单抗。
- 伊匹木单抗/纳武利尤单抗发生≥3级治疗相关不良事件的风险最高。
- 瑞拉利单抗/纳武利尤单抗相比伊匹木单抗/纳武利尤单抗,≥3级治疗相关不良事件风险有降低趋势(RR=0.71,95%CI 0.30-1.67)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment options for advanced melanoma have increased with the US Food and Drug Administration approval of the anti-LAG3 plus anti-PD-1 relatlimab/nivolumab combination. To date, ipilimumab/nivolumab is the benchmark of overall survival, despite a high toxicity profile. Furthermore, in BRAF-mutant patients, BRAF/MEK inhibitors and the atezolizumab/vemurafenib/cobimetinib triplet are also available treatments, making the first-line therapy selection more complex. To address this issue, we conducted a systematic review and network meta-analysis of the available first-line treatment options in advanced melanoma. METHODS: Randomised clinical trials of previously untreated, advanced melanoma were included if at least one intervention arm contained a BRAF/MEK or an immune-checkpoint inhibitor (ICI). The aim was to indirectly compare the ICIs combinations ipilimumab/nivolumab and relatlimab/nivolumab, and these combinations with all the other first-line treatment options for advanced melanoma (irrespective of BRAF status) in terms of activity and safety. The coprimary end-points were progression-free survival (PFS), overall response rate (ORR) and grade ≥3 treatment-related adverse events (≥ G3 TRAEs) rate, defined according to Common Terminology Criteria for Adverse Events. RESULTS: A total of 9070 metastatic melanoma patients treated in 18 randomised clinical trials were included in the network meta-analysis. No difference in PFS and ORR was observed between ipilimumab/nivolumab and relatlimab/nivolumab (HR = 0.99 [95% CI 0.75-1.31] and RR = 0.99 [95% CI 0.78-1.27], respectively). The PD-(L)1/BRAF/MEK inhibitors triplet combinations were superior to ipilimumab/nivolumab in terms of both PFS (HR = 0.56 [95% CI 0.37-0.84]) and ORR (RR = 3.07 [95% CI 1.61-5.85]). Ipilimumab/nivolumab showed the highest risk of developing ≥ G3 TRAEs. Relatlimab/nivolumab trended to a lower risk of ≥ G3 TRAEs (RR = 0.71 [95% CI 0.30-1.67]) versus ipilimumab/nivolumab. CONCLUSION: Relatlimab/nivolumab showed similar PFS and ORR compared to ipilimumab/nivolumab, with a trend for a better safety profile.
引用
- Boutros A, Tanda ET, Croce E, et al. Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis. Eur J Cancer. 2023. PMID: 37196485. doi:10.1016/j.ejca.2023.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。